Active Ingredient History

  • Now
Fluoxymesterone, sold under the brand names Halotestin and Ultandren among others, is a synthetic, orally active androgenic-anabolic steroid (AAS) and a 17α-alkylated derivative of testosterone developed by Pharmacia & Upjohn Company LLC, approved by FDA at 1956. Fluoxymesterone is used in the treatment of hypogonadism in males and breast cancer in women. Fluoxymesterone has a relatively high ratio of androgenic to anabolic activity similarly to testosterone. Like many 17α-alkylated AAS, it has a relatively low affinity for the androgen receptor (AR). However, its actions are mediated by the AR, most likely due to its relatively long elimination half-life of approximately 9.2 hours.   NCATS

  • SMILES: C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C
  • Mol. Mass: 336.4409
  • ALogP: 3.33
  • ChEMBL Molecule:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No
11beta,17beta-dihydroxy-9alpha-fluoro-17alpha-methyl-4-androster-3-one | 17alpha-methyl-9alpha-fluoro-11beta-hydroxytesterone | 17α-methyl-9α-fluoro-11β-hydroxytesterone | 9alpha-fluoro-11beta-hydroxy-17-methyltestosterone | 9-fluoro-11beta,17beta-dihydroxy-17-methylandrost-4-en-3-one | androfluorene | androfluorone | android-f | androxy | fluotestin | fluoximesterona | fluoximesterone | fluoxymesterone | fluoxymesteronum | halotestin | ora-testryl | testosterone, 9-fluoro-11beta-hydroxy-17-methyl-


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue